For the quarter ending 2025-09-30, SSKN had $1,110K increase in cash & cash equivalents over the period. -$1,082K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,398 | -4,921 |
| Depreciation and amortization | 864 | 2,438 |
| Amortization of operating lease right-of-use assets | 87 | 172 |
| Amortization of deferred financing costs and debt discount | 40 | 78 |
| Change in allowance for credit losses | -50 | 166 |
| Stock-based compensation expense | 212 | 257 |
| Loss on disposal of property and equipment | -20 | -63 |
| Settlement gains | 684 | - |
| Inventory write-off | 0 | 0 |
| Accounts receivable | -568 | -1,065 |
| Inventories | -282 | 912 |
| Prepaid expenses and other assets | 84 | 49 |
| Accounts payable | 9 | 465 |
| Accrued expenses and other liabilities | 1 | -1,201 |
| Deferred revenues | 150 | 52 |
| Operating lease liabilities | -81 | -164 |
| Net cash used in operating activities | -64 | -2,491 |
| Purchase of property and equipment | 1,018 | 138 |
| Net cash used in investing activities | -1,018 | -138 |
| Payment of contingent consideration | 0 | 0 |
| Sale of common stock, net of offering costs | 2,192 | - |
| Net cash provided by financing activities | 2,192 | 0 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 1,110 | -2,629 |
| Cash and cash equivalents at beginning of period | 8,595 | - |
| Cash and cash equivalents at end of period | 7,076 | - |
STRATA Skin Sciences, Inc. (SSKN)
STRATA Skin Sciences, Inc. (SSKN)